IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial
Sima, L.1; Fang, W. X.2; Wu, X. M.3,4; Li, F.5
关键词Oxycodone Pain Paracetamol
刊名JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
2012-02-01
DOI10.1111/j.1365-2710.2010.01239.x
37期:1页:27-31
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]CONTROLLED-RELEASE OXYCODONE ; NONSTEROIDAL ANTIINFLAMMATORY DRUGS ; NEUROPATHIC PAIN ; ACETAMINOPHEN ; MANAGEMENT
英文摘要

What is known and Objective: Bone-cancer pain is a common and refractory cancer pain. Opioids, on their own, do not control this type of pain well enough, and co-analgesics are necessary.

Methods: Patients with bone metastasis-related pain at Numeric Rating Scale 4 were enrolled to this randomized placebo-controlled trial. They had also received morphine or transdermal fentanyl patches for at least 1 week. During the 3-day efficacy phase, patients received placebo or 1-3 tablets of oxycodone/paracetamol (5/325 mg), four times daily for 3 days. All patients kept a daily pain diary. The primary endpoint was the Pain Intensity Difference (PID). Secondary endpoints were cases of breakthrough pain and rescue morphine consumption. Additional analyses included the Short Form-6 Dimensions (SF-6D) quality-of-life scale and a general impression (GI) of patient satisfaction with treatment at the end of the phase.

Results and Discussion: Of the 246 patients in the intent-to-treat set, 89.4% completed the 3-day efficacy phase. PIDs were 0.9 and 0.3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0.001), and 1.5 and 0.3 respectively on day 3 (P < 0.001). Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0.001). The SF-6D score decreased to 21.2 +/- 2.5 in the oxycodone/paracetamol group at the end of the phase (P = 0.001). In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.

What is new and Conclusion: Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.

语种英语
WOS记录号WOS:000299549500005
引用统计
被引频次:10[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57058
专题北京大学第一临床医学院
作者单位1.China Japan Friendship Hosp, Natl Pain Management & Res Ctr, Beijing 100029, Peoples R China
2.Peking Univ, Dept Anesthesia, Hosp 1, Beijing 100871, Peoples R China
3.Chinese Acad Med Sci, Dept Polyclin, Canc Inst & Hosp, Beijing 100730, Peoples R China
4.Peking Union Med Coll, Beijing 100021, Peoples R China
5.Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Sima, L.,Fang, W. X.,Wu, X. M.,et al. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial[J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS,2012,37(1):27-31.
APA Sima, L.,Fang, W. X.,Wu, X. M.,&Li, F..(2012).Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial.JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS,37(1),27-31.
MLA Sima, L.,et al."Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial".JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS 37.1(2012):27-31.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sima, L.]的文章
[Fang, W. X.]的文章
[Wu, X. M.]的文章
百度学术
百度学术中相似的文章
[Sima, L.]的文章
[Fang, W. X.]的文章
[Wu, X. M.]的文章
必应学术
必应学术中相似的文章
[Sima, L.]的文章
[Fang, W. X.]的文章
[Wu, X. M.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。